Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jamjoom Pharmaceuticals Factory CoSAU:4015 +0.28%98 Return-on-Tangible-Asset is 24.94% as of Jun. 2026, which is 50% above its 10-year median of 16.63. GuruFocus rates SAU:4015 with a GF Score™ of 98/100 and a GF Value™ of ﷼178.81 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,007 Drug Manufacturers companies, Jamjoom Pharmaceuticals Factory Co ranks better than 95.63% on this metric.
The historical rank and industry rank for Jamjoom Pharmaceuticals Factory Co's Return-on-Tangible-Asset or its related term are showing as below:
SAU:4015'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 11.79 Med: 16.63 Max: 24.49
Current: 22.79
During the past 6 years, Jamjoom Pharmaceuticals Factory Co's highest Return-on-Tangible-Asset was 24.49%. The lowest was 11.79%. And the median was 16.63%.
SAU:4015's Return-on-Tangible-Asset is ranked better than 95.63% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.04
vs SAU:4015: 22.79
Jamjoom Pharmaceuticals Factory Co (SAU:4015) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Jamjoom Pharmaceuticals Factory Co Return-on-Tangible-Asset Related Terms
Jamjoom Pharmaceuticals Factory Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jamjoom Pharmaceuticals Factory Co Return-on-Tangible-Asset Chart
SAU:4015 vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jamjoom Pharmaceuticals Factory Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jamjoom Pharmaceuticals Factory Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jamjoom Pharmaceuticals Factory Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Jamjoom Pharmaceuticals Factory Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 24.94% mean?
Jamjoom Pharmaceuticals Factory Co (SAU:4015) has a Return-on-Tangible-Asset of 24.94% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Jamjoom Pharmaceuticals Factory Co and its competitors. This is 50% above median its historical median of 16.63. Over the past decade, Jamjoom Pharmaceuticals Factory Co's Return-on-Tangible-Asset has ranged from 11.79 to 24.49. According to the industry distribution chart, Jamjoom Pharmaceuticals Factory Co ranks #44 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 4.4%.
Is Jamjoom Pharmaceuticals Factory Co's Return-on-Tangible-Asset too high?
Jamjoom Pharmaceuticals Factory Co's current Return-on-Tangible-Asset of 24.94% is 50% above median its 10-year median of 16.63. Over the past 10 years, this metric has ranged from a low of 11.79 to a high of 24.49. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.04. Jamjoom Pharmaceuticals Factory Co's value of 24.94% is 720.4% above this industry median. Based on the distribution chart, Jamjoom Pharmaceuticals Factory Co ranks #44 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jamjoom Pharmaceuticals Factory Co has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jamjoom Pharmaceuticals Factory Co's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jamjoom Pharmaceuticals Factory Co ranks #44 out of 1007 companies for Return-on-Tangible-Asset. This places Jamjoom Pharmaceuticals Factory Co in the top 4% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.04. Jamjoom Pharmaceuticals Factory Co's value of 24.94% is 720.4% above this benchmark. Historically, Jamjoom Pharmaceuticals Factory Co's own Return-on-Tangible-Asset has ranged from 11.79 to 24.49 over the past decade. While the company's 10-year median is 16.63 vs. the industry median of 3.04, Jamjoom Pharmaceuticals Factory Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.04, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jamjoom Pharmaceuticals Factory Co's current Return-on-Tangible-Asset of 24.94% is 720.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Jamjoom Pharmaceuticals Factory Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jamjoom Pharmaceuticals Factory Co's current Return-on-Tangible-Asset is 24.94%, which is 50% above median its own 10-year median of 16.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jamjoom Pharmaceuticals Factory Co stock overvalued right now?
Based on GuruFocus' analysis, Jamjoom Pharmaceuticals Factory Co (SAU:4015) is currently considered Modestly Undervalued. The stock's GF Value™ is ﷼178.81, compared to a current price of ﷼142.00 — trading 20.6% below its estimated fair value. The current Return-on-Tangible-Asset is 24.94%, which is 50% above median its 10-year median of 16.63 and 720.4% above the Drug Manufacturers industry median of 3.04. Jamjoom Pharmaceuticals Factory Co's overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Jamjoom Pharmaceuticals Factory Co (SAU:4015), the current Return-on-Tangible-Asset is 24.94% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jamjoom Pharmaceuticals Factory Co (SAU:4015) Overvalued in 2026?
Based on GuruFocus' analysis, Jamjoom Pharmaceuticals Factory Co stock appears to be undervalued.
The current stock price of ﷼142.00 is trading 20.6% below its estimated GF Value™ of ﷼178.81.
GuruFocus considers Jamjoom Pharmaceuticals Factory Co to be Modestly Undervalued.
Key valuation signals for SAU:4015:
Return-on-Tangible-Asset: 24.94% (50% above median its 10-year median of 16.63)
GF Value™: ﷼178.81 vs. price of ﷼142.00 (20.6% below fair value)
Industry Position: 720.4% above the Drug Manufacturers median (#44 of 1007)
No single metric tells the full story. See the SAU:4015 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jamjoom Pharmaceuticals Factory Co is engaged in producing human medicines, nutraceuticals, antibiotics, general analgesics, medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, ulcer and acidity, treatment of various skin infections, cancer diseases, eye drops and ointments and cosmeceuticals. Geographically the company has a presence in the Kingdom of Saudi Arabia, the Gulf, Iraq, Egypt, North Africa, and other export markets.
98GF Score
Get the complete analysis for SAU:4015
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4015 has been successfully added to your 
